Kirsten rat sarcoma (KRAS) is the most frequently mutated oncogene and is associated with several highly fatal cancers. Exceptional recent advances have resulted in drug candidates for this target which was once considered undruggable. Adagrasib (MRTX849, 1, Figure ) is a therapy for treatment of non-small cell lung cancer which results from G12C point mutation to the KRAS gene. The NDA filing for this drug candidate is under FDA review with a decision to be made in December, 2022. Supporting further clinical combination trials and commercial manufacture for sizable patient populations requires ability to consistently produce ton scale quantities with a high degree of control. This publication communicates those efforts.